Large-Scale Study Validates Multi-Cancer Blood Test Performance
A real-world study of 111,080 participants found the Galleri multi-cancer blood test achieved a 0.91% cancer detection rate and 87% accuracy in predicting tumor origin.
A real-world study of 111,080 participants found the Galleri multi-cancer blood test achieved a 0.91% cancer detection rate and 87% accuracy in predicting tumor origin.
The collaboration will combine New Day's liquid biopsy technology with Daisy Genomics' physics-based sequencing platform to advance early CRC screening.
Researchers found that circulating tumor cell counts stratified patients by disease aggressiveness and were associated with differing outcomes following endocrine versus combination therapy.
A blinded validation in more than 400 women shows the test provides clearer guidance on recurrence risk and radiation therapy decisions.
Read MoreJohns Hopkins researchers found the blood test detected multiorgan tissue damage in patients experiencing immune-related adverse events from checkpoint inhibitor therapy.
Read MoreA study of 431 patients demonstrates the test can detect cancer recurrence months ahead of standard imaging.
Read MoreResearch analyzing cell-free DNA fragmentation patterns in healthy individuals reveals physiological confounders that could improve test accuracy.
Read MoreTransaction expands Natera’s solid tumor MRD capabilities and adds ultrasensitive phased variant technology with detection below 0.1 parts per million.
Read MoreThe collaboration combines AI-based analysis tools with a next-generation sequencing system to support labs performing tumor and liquid biopsy testing.
Read MoreThe new guidelines allow self-collected vaginal samples for HPV testing and outline criteria for safely discontinuing cervical cancer screening.
Read MoreThe test receives premarket approval as an aid in biopsy decision-making for men 50 and older with elevated PSA levels.
Read MoreThe Mercy Halo test demonstrates performance similar to low-dose CT screening with the potential to reach underscreened populations.
Read MoreThe standards developed through a public-private partnership contain seven oncogenic mutations selected for clinical significance.
Read MoreCoverage applies to stage II and III breast cancer patients across three major subtypes for up to six years of recurrence monitoring.
Read MoreResearch demonstrates the MRD assay’s utility in tracking disease progression and predicting treatment outcomes.
Read MoreThe blood-based screening test can detect more than 200 types of solid tumor cancers and is now available in all 48 continental states.
Read MoreThe agreement extends CNSide cerebrospinal fluid test coverage to 16 million additional patients nationwide.
Read MoreThe whole-genome test combines data from 7 million genetic markers with clinical risk factors to provide individualized 10-year and lifetime risk assessments.
Read More